George Demetri, MD

Dana-Farber Cancer Institute – Sarcoma Center; IDRx
Boston, Massachusetts, United States

Disclosure information not submitted.

Presentation(s):

• Paper 10 - THE NOVEL KIT INHIBITOR IDRX-42 SHOWS PROMISING ACTIVITY IN 2ND AND LATER-LINE GASTROINTESTINAL STROMAL TUMORS: RESULTS FROM A PHASE 1 STUDY (STRATEGIST 1)

  Thursday, November 14, 2024
  10:30 AM – 11:30 AM PST